Related Experiment Video
Updated: Jan 22, 2026

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Celastrol attenuates ox-LDL-induced mesangial cell proliferation via suppressing NLRP3 inflammasome activation
Zhenzhen Sun1,2,3, Yuanyuan Li1,2,3, Yun Qian1,2,3
11Department of Nephrology, Children's Hospital of Nanjing Medical University, Guangzhou Road #72, 210008 Nanjing, China.
Abstract:
Mesangial cell (MC) proliferation is one of the important pathological features of obesity-associated nephropathy with unknown etiology. Excessive MC proliferation can cause glomerulosclerosis and renal function loss. Thus, targeting MC proliferation may be a potential strategy for the treatment of obesity-associated kidney disease. The present study was undertaken to investigate the role of celastrol in MC proliferation induced by ox-LDL, as well as the potential mechanisms. Following ox-LDL treatment, MC proliferation was induced and the NLRP3 inflammasome was activated, as evidenced by increased NLRP3 levels, caspase 1 activity, and IL-18 and IL-1β release. Significantly, NLRP3 siRNAs inhibited MC proliferation and delayed cell cycle progression, as indicated by the cell cycle assay and the expression of cyclin A2 and cyclin D1. Given the anti-inflammatory effect of celastrol, we pretreated MCs with celastrol before ox-LDL treatment. As expected, celastrol pretreatment strikingly inhibited NLRP3 inflammasome activation and MC proliferation triggered by ox-LDL. In summary, celastrol potently blocked ox-LDL-induced MC proliferation, possibly by inhibiting NLRP3 inflammasome activation. These findings also suggest that celastrol may be a potential drug for treating proliferative glomerular diseases related to obesity and lipid disorders.
Insights
Celastrol inhibits mesangial cell proliferation and NLRP3 inflammasome activation induced by oxidized LDL. This suggests celastrol may treat obesity-related kidney disease and proliferative glomerular disorders.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Mesangial cell (MC) proliferation is a key feature of obesity-associated nephropathy, potentially leading to glomerulosclerosis and kidney dysfunction.
- Targeting MC proliferation offers a therapeutic strategy for obesity-related kidney disease.
Purpose of the Study:
- To investigate celastrol's role in inhibiting oxidized low-density lipoprotein (ox-LDL)-induced MC proliferation.
- To elucidate the underlying mechanisms involving the NLRP3 inflammasome.
Main Methods:
- MCs were treated with ox-LDL, with or without celastrol pretreatment.
- NLRP3 inflammasome activation was assessed by measuring NLRP3 levels, caspase 1 activity, and IL-1β/IL-18 release.
- MC proliferation and cell cycle progression were evaluated using cell cycle assays and cyclin A2/D1 expression analysis.
- NLRP3 inflammasome was inhibited using NLRP3 siRNAs.
Main Results:
- Ox-LDL treatment induced MC proliferation and activated the NLRP3 inflammasome.
- NLRP3 siRNA significantly inhibited MC proliferation and delayed cell cycle progression.
- Celastrol pretreatment markedly suppressed ox-LDL-induced NLRP3 inflammasome activation and MC proliferation.
Conclusions:
- Celastrol effectively inhibits ox-LDL-induced mesangial cell proliferation, likely by suppressing NLRP3 inflammasome activation.
- Celastrol shows potential as a therapeutic agent for obesity-related proliferative glomerular diseases and lipid disorders.
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Cells Coordinate Growth and Proliferation
Abnormal Proliferation
Induced Pluripotent Stem Cells
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

